The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised Medicine

Abstract: Precise staging of pancreatic cancer is crucial for treatment choice. In clinical practice, this includes the TNM staging and determination of tumour resectability, based on a multimodality imaging workup. International guidelines recommend multi-detector computed tomography (CT), with a dedicated pancreatic protocol, as the first-line tool for TNM staging and evaluation of tumour-vessel relationships. In non-metastatic disease upon initial CT assessment, both magnetic resonance imaging and endoscopic ultrasound (EUS) may add relevant information, potentially changing treatment sequence. EUS may have distinct advantages in pancreatic cancer diagnosis and staging when compared with other modalities, being particularly valuable in the determination of portal venous confluence involvement (particularly in small and ill defined/isoattenuating tumours on CT), in locoregional nodal staging and in the detection of ascites. As we step forward to a more frequent use of neoadjuvant chemotherapy and to personalised medicine, the importance of EUS-guided fine-needle biopsy (EUS-FNB) also increases. The recent availability of third-generation biopsy needles significantly increased the diagnostic yield of EUS-guided tissue acquisition, providing diagnostic cell blocks in approximately 95% of cases with only two dedicated passes and allowing ancillary testing, such as immunohistochemistry and molecular profiling of the tumour. In this article, the authors present an updated perspective of the place of EUS and EUS-FNB in the staging algorithm of pancreatic cancer. Data supporting the increasing role of neoadjuvant therapy and the importance of a patient tailored treatment selection, based on tumoural subtyping and molecular profiling, are also discussed.

Saved in:
Bibliographic Details
Main Authors: Bispo,Miguel, Marques,Susana, Rio-Tinto,Ricardo, Fidalgo,Paulo, Devière,Jacques
Format: Digital revista
Language:English
Published: Sociedade Portuguesa de Gastrenterologia 2021
Online Access:http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452021000200111
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2341-45452021000200111
record_format ojs
spelling oai:scielo:S2341-454520210002001112022-01-13The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised MedicineBispo,MiguelMarques,SusanaRio-Tinto,RicardoFidalgo,PauloDevière,Jacques Endoscopic ultrasound Fine-needle biopsy Neoadjuvant therapy Pancreatic cancer staging Personalised medicine Precision therapy Abstract: Precise staging of pancreatic cancer is crucial for treatment choice. In clinical practice, this includes the TNM staging and determination of tumour resectability, based on a multimodality imaging workup. International guidelines recommend multi-detector computed tomography (CT), with a dedicated pancreatic protocol, as the first-line tool for TNM staging and evaluation of tumour-vessel relationships. In non-metastatic disease upon initial CT assessment, both magnetic resonance imaging and endoscopic ultrasound (EUS) may add relevant information, potentially changing treatment sequence. EUS may have distinct advantages in pancreatic cancer diagnosis and staging when compared with other modalities, being particularly valuable in the determination of portal venous confluence involvement (particularly in small and ill defined/isoattenuating tumours on CT), in locoregional nodal staging and in the detection of ascites. As we step forward to a more frequent use of neoadjuvant chemotherapy and to personalised medicine, the importance of EUS-guided fine-needle biopsy (EUS-FNB) also increases. The recent availability of third-generation biopsy needles significantly increased the diagnostic yield of EUS-guided tissue acquisition, providing diagnostic cell blocks in approximately 95% of cases with only two dedicated passes and allowing ancillary testing, such as immunohistochemistry and molecular profiling of the tumour. In this article, the authors present an updated perspective of the place of EUS and EUS-FNB in the staging algorithm of pancreatic cancer. Data supporting the increasing role of neoadjuvant therapy and the importance of a patient tailored treatment selection, based on tumoural subtyping and molecular profiling, are also discussed.info:eu-repo/semantics/openAccessSociedade Portuguesa de GastrenterologiaGE-Portuguese Journal of Gastroenterology v.28 n.2 20212021-04-01info:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452021000200111en10.1159/000509197
institution SCIELO
collection OJS
country Portugal
countrycode PT
component Revista
access En linea
databasecode rev-scielo-pt
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Bispo,Miguel
Marques,Susana
Rio-Tinto,Ricardo
Fidalgo,Paulo
Devière,Jacques
spellingShingle Bispo,Miguel
Marques,Susana
Rio-Tinto,Ricardo
Fidalgo,Paulo
Devière,Jacques
The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised Medicine
author_facet Bispo,Miguel
Marques,Susana
Rio-Tinto,Ricardo
Fidalgo,Paulo
Devière,Jacques
author_sort Bispo,Miguel
title The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised Medicine
title_short The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised Medicine
title_full The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised Medicine
title_fullStr The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised Medicine
title_full_unstemmed The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised Medicine
title_sort role of endoscopic ultrasound in pancreatic cancer staging in the era of neoadjuvant therapy and personalised medicine
description Abstract: Precise staging of pancreatic cancer is crucial for treatment choice. In clinical practice, this includes the TNM staging and determination of tumour resectability, based on a multimodality imaging workup. International guidelines recommend multi-detector computed tomography (CT), with a dedicated pancreatic protocol, as the first-line tool for TNM staging and evaluation of tumour-vessel relationships. In non-metastatic disease upon initial CT assessment, both magnetic resonance imaging and endoscopic ultrasound (EUS) may add relevant information, potentially changing treatment sequence. EUS may have distinct advantages in pancreatic cancer diagnosis and staging when compared with other modalities, being particularly valuable in the determination of portal venous confluence involvement (particularly in small and ill defined/isoattenuating tumours on CT), in locoregional nodal staging and in the detection of ascites. As we step forward to a more frequent use of neoadjuvant chemotherapy and to personalised medicine, the importance of EUS-guided fine-needle biopsy (EUS-FNB) also increases. The recent availability of third-generation biopsy needles significantly increased the diagnostic yield of EUS-guided tissue acquisition, providing diagnostic cell blocks in approximately 95% of cases with only two dedicated passes and allowing ancillary testing, such as immunohistochemistry and molecular profiling of the tumour. In this article, the authors present an updated perspective of the place of EUS and EUS-FNB in the staging algorithm of pancreatic cancer. Data supporting the increasing role of neoadjuvant therapy and the importance of a patient tailored treatment selection, based on tumoural subtyping and molecular profiling, are also discussed.
publisher Sociedade Portuguesa de Gastrenterologia
publishDate 2021
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452021000200111
work_keys_str_mv AT bispomiguel theroleofendoscopicultrasoundinpancreaticcancerstagingintheeraofneoadjuvanttherapyandpersonalisedmedicine
AT marquessusana theroleofendoscopicultrasoundinpancreaticcancerstagingintheeraofneoadjuvanttherapyandpersonalisedmedicine
AT riotintoricardo theroleofendoscopicultrasoundinpancreaticcancerstagingintheeraofneoadjuvanttherapyandpersonalisedmedicine
AT fidalgopaulo theroleofendoscopicultrasoundinpancreaticcancerstagingintheeraofneoadjuvanttherapyandpersonalisedmedicine
AT devierejacques theroleofendoscopicultrasoundinpancreaticcancerstagingintheeraofneoadjuvanttherapyandpersonalisedmedicine
AT bispomiguel roleofendoscopicultrasoundinpancreaticcancerstagingintheeraofneoadjuvanttherapyandpersonalisedmedicine
AT marquessusana roleofendoscopicultrasoundinpancreaticcancerstagingintheeraofneoadjuvanttherapyandpersonalisedmedicine
AT riotintoricardo roleofendoscopicultrasoundinpancreaticcancerstagingintheeraofneoadjuvanttherapyandpersonalisedmedicine
AT fidalgopaulo roleofendoscopicultrasoundinpancreaticcancerstagingintheeraofneoadjuvanttherapyandpersonalisedmedicine
AT devierejacques roleofendoscopicultrasoundinpancreaticcancerstagingintheeraofneoadjuvanttherapyandpersonalisedmedicine
_version_ 1756004342017556480